4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based study
This population-based analysis of patients with stage III melanoma demonstrated no significant 4-year OS benefit after the introduction of adjuvant therapy. Pending the OS results of the randomized trials, the potential benefits and risks of adjuvant therapy should be carefully weighed for patients with stage III melanoma.
Authors
- AAM van der Veldt
- J.C. Janssen
- Louwman M.W.J.
- D. Grünhagen
- A.W. Schurink
- C. Verhoef
- E. Oomen-de Hoop
Institutions
- Netherlands Comprehensive Cancer Organisation (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1016/j.ejca.2025.116202
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00